AtriCure to Announce Second Quarter 2013 Financial Results

Before you go, we thought you'd like these...
Before you go close icon

AtriCure to Announce Second Quarter 2013 Financial Results

WEST CHESTER, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (NAS: ATRC) , a medical device company and a leader in the development of technologies and solutions for the treatment of atrial fibrillation, or Afib, and systems for the exclusion of the left atrial appendage, will release its financial results for the second quarter of 2013 on Thursday, August 1, 2013.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 1, 2013 to discuss its second quarter 2013 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure's corporate website at

Pre-registration is available and recommended for this call at the following URL:

You may also access this call through an operator by calling (888) 713-4211 for domestic callers and (617) 213-4864 for international callers at least 15 minutes prior to the call start time using reservation code 51971753.

The webcast will be available on AtriCure's website and a telephonic replay of the call will also be available through September 1, 2013. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. The reservation code is 22164965.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative Atrial Fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of Atrial Fibrillation. AtriCure's Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure's AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide. The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
Investor Relations Contact:
Westwicke Partners
Lynn Pieper, 415-202-5678

KEYWORDS:   United States  North America  Ohio


The article AtriCure to Announce Second Quarter 2013 Financial Results originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading